BOSTON--(BUSINESS WIRE)--PureTech Health plc (LSE: PRTC, Nasdaq: PRTC) (PureTech or the Company), a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases, will host its first R&D Day on Friday, December 11, 2020, beginning at 9:00 a.m., Eastern Time. The virtual program will showcase PureTechs scientific leadership in lymphatics and related immune pathways and share insights across its Wholly Owned Pipeline, which includes LYT-100, a clinical-stage anti-fibrotic and anti-inflammatory product candidate being advanced for the potential treatment of interstitial lung diseases and lymphedema, and LYT-200, a product candidate targeting foundational immunomodulatory mechanisms for the potential treatment of solid tumors.

In addition to presentations by PureTechs senior team, the R&D Day will feature talks from renowned scientists and physicians, including:

PureTechs inaugural R&D Day is an opportunity to bring together field-leading experts within our expansive global network to discuss the unique therapeutic opportunities within lymphatics and related immunology, said Daphne Zohar, chief executive officer of PureTech Health. We have made great progress across our Wholly Owned Pipeline, which now includes four product candidates and three discovery platforms, and we look forward to detailing our differentiated approach towards addressing major diseases.

The agenda for PureTechs R&D Day is:

Opening Remarks

Lymphatic Science Overview

Fibrotic and Inflammatory Conditions Unmet Need and LYT-100

Immuno-Oncology Prioritizing Targets and Future Directions

Closing Remarks

A webcast of the event will be available on the Investors section of PureTechs website under Events & Presentations.

To register for PureTechs R&D Day, please sign up here.

About PureTech Health

PureTech is a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases, including intractable cancers, lymphatic and gastrointestinal diseases, central nervous system disorders and inflammatory and immunological diseases, among others. The Company has created a broad and deep pipeline through the expertise of its experienced research and development team and its extensive network of scientists, clinicians and industry leaders. This pipeline, which is being advanced both internally and through PureTechs Founded Entities, is comprised of 24 products and product candidates, including two that have received U.S. Food and Drug Administration (FDA) clearance and European marketing authorization. All of the underlying programs and platforms that resulted in this pipeline of product candidates were initially identified or discovered and then advanced by the PureTech team through key validation points based on the Companys unique insights into the biology of the brain, immune and gut, or BIG, systems and the interface between those systems, referred to as the BIG Axis.

For more information, visit http://www.puretechhealth.com or connect with us on Twitter @puretechh.

Cautionary Note Regarding Forward-Looking Statements

This press release contains statements that are or may be forward-looking statements, including statements that relate to our product candidates and approach towards addressing major diseases, future prospects, developments, and strategies. The forward-looking statements are based on current expectations and are subject to known and unknown risks and uncertainties that could cause actual results, performance and achievements to differ materially from current expectations, including, but not limited to, our expectations regarding the potential therapeutic benefits of PureTechs product candidates and those risks and uncertainties described in the risk factors included in the regulatory filings for PureTech Health plc. These forward-looking statements are based on assumptions regarding the present and future business strategies of the company and the environment in which it will operate in the future. Each forward-looking statement speaks only as at the date of this press release. Except as required by law and regulatory requirements, neither the company nor any other party intends to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.

Original post:
PureTech to Host Virtual R&D Day for Investors on December 11, 2020 - Business Wire